In my latest Guest Column in The Evidence Base, II am joined by my colleague Tiago Beck as we examine how global pricing reforms are reshaping the European pharmaceutical landscape. Building on their session at ISPOR Europe 2025, the column explores the growing tension between EU access ambitions and international policy pressures – offering a…
Marie Noon takes eight medications a day. One keeps her heart rate from spiking to avoid a stroke. One prevents debilitating headaches. Another ensures she doesn’t retain excess fluid. More than a decade ago, Noon said, she was diagnosed with adult-onset Still’s disease, a rare type of inflammatory arthritis that can cause rashes, debilitating pain,…
Every state, along with Washington, D.C., requires children to obtain certain vaccinations before they can attend school or childcare. These mandates date back decades, and many public health experts consider them a foundational defense against infectious disease. Since the summer of 2025, Florida leaders have aimed to make the state the first to drop some…
HTI-5 proposes significant regulatory updates, including removing over half of certification criteria
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is that not only is this terrible for patient health, it can be more costly in the end. The post The True Cost of Focusing on Cost Instead of Cost-Effectiveness appeared…
This analysis estimates the number of states impacted by and the amount of current federal spending on Medicaid state directed payments for hospital services that exceeds the new limits established by the 2025 reconciliation law when fully implemented.
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions. The post FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions appeared first on MedCity News.
Providers need a revenue cycle management platform that is more affordable and accurate, said Jeremy Dekinsky, CEO of Smarter Technologies, during MedCity News’ INVEST conference. New Mountain Capital formed Smarter Technologies this week by combining three separate platforms it had already acquired. The post How a New PE-Backed RCM Company Plans to Fix the ‘Transactional…
The future of hospital operations will be defined not by who has the most AI, but by who can turn AI into consistent, reliable operational outcomes. The post Ensuring AI Investments Deliver on Their Promise in 2026: Why Outcomes, not Algorithms, Will Define Success appeared first on MedCity News.
Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas. CEO Reshma Kewalramani explained Vertex’s strategy during the World Medical Innovation Forum in Boston. The post Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis…